The spontaneous electroencephalogram (EEG) was recorded after the intramuscular (IM) injection of morphine sulfate (15, 30 mg) or saline (0.9% NaCl). Correlations between changes in EEG spectral power and subjective self-reports, as measured on subscales of the Addiction Research Center Inventory (ARC!), were evaluated. Morphine increased alphaJ and alpha2 power and theta power, and attenuated the increase in delta power observed after placebo. Positive correlations were found between the change in alpha1, alpha2, beta1, and beta2 power in response to 30 mg of morphine and scores
The subjective effects of opioids have been studied ex tensively in human volunteers (Martin 1983 ). Morphine produces a wide variety of effects, including analgesia, drowsiness, changes in mood, and mental clouding Gaff e and Martin 1985) . In detoxifIed volunteers with histories of opioid abuse, arousal is produced (Kay et aI. 1969) , mental clouding is less prominent, and posi tive effects on mood are more pronounced than in nor-on Morphine-Benzedrine Group (MBG) subscale of the ARC!. Negative relationships were observed between changes in alpha1, and beta2 and scores on the Pentobarbital Chlorpromazine Alcohol Group (PCAG) subscale. The findings indicate that positive subjective effects of opioids, as measured by the MBG subscale, are related to increases in alpha and beta activity and are associated with reduction of opioid-induced sedation, as measured by the PCAG subscale. [Neuropsychopharmacology 10:171-181, 1994] mal subjects (von Felsinger et al. 1955) . Although con siderable information about the actions of opioid drugs in the nervous system exists, little is known about the central mechanisms underlying their effects on mood and feeling state in human subjects.
Effects of morphine on the electroencephalogram (EEG) have been tested in several species. In rats, opi oids increase the abundance of low frequencies in the EEG (Wikler 1954; Khazan and Colasanti 1971; Young et al. 1980; Khazan 1984, 1986) . In the dog, periods of burst-slow activity have been observed (Wik ler 1952) . Slowing of the EEG is observed in the cat as well (De Andres and Caballero 1989) .
Opioid-induced slowing of the EEG in human sub jects was &rst discovered by visual observation of EEG tracings (Berger 1937; Andrews 1941 Andrews , 1943 Gibbs and Maltby 1943) . Slowing has been de&ned in several ways. Earlier studies de&ned slowing as a decrease in the dom inant frequency of the EEG tracings (Fig. la) or as the appearance of bursts of slow wave activity (Fig. Ib) . Later studies using more quantitative methods de&ned slowing as a decrease in the alpha frequency ( or as an increase in low frequency (delta and/or theta)
power (Fig. 1d) . A decrease in the dominant frequency of the EEG tracing can be due either to a decrease in alpha frequency, a decrease in alpha power relative to delta and/or theta power, or an increase in delta and/or theta power (Lukas 1991) .
Effects of opioids on the EEG of human subjects with a history of opioid abuse have been reported. Both heroin and methadone decreased alpha frequency and increased delta and theta abundance (Fink et al. 1971; Volavka et al. 1979) . Biphasic EEG effects of intrave nous heroin have been reported. Increased alpha power and decreased alpha frequency were found during the fIrst 2 to 3 minutes; after 3 to 5 minutes, a decrease in alpha amplitude and an increase in theta abundance oc curred (Volavka et al. 1970) . Kay et al. (1969) reported diminished amplitude of delta waves with an increased incidence of unusual EEG patterns such as bursts of multiple frequency waves and mixtures of alpha and delta.
Effects of opioids on the EEG vary with the drug histories of the subjects. In surgical patients, the inject able opioid anesthetics, fentanyl, sufentanil, and alfen tanil, increased abundance of EEG delta power and de creased abundance of alpha and/or beta power (Sebel et al. 1981; Bovill et al. 1983; Smith et al. 1984; Wau quier et al. 1984; Bromm et al. 1989; Scott et al. 1991) . In contrast, in normal, pain-free human subjects, a small decrease in delta, an increase in slow alpha with a de crease in relative fast alpha, and an increase in beta power occurred 1 to 2 hours after subcutaneous administra tion of morphine (4 and 8 mg) (Matejcek et al. 1988 ). These changes were accompanied by signihcant in creases in self-reports of drowsiness, lethargy, and me n tal slowness. Opioid-naive subjects gave self-reports of being dizzy, nauseous, itchy, warm, and headachy more often in response to morphine than to placebo (Beecher 1959) .
Despite differences in the specilic opioid drugs and doses and populations tested, increased EEG slow wave activity (delta and/or theta abundance) has been the common response to opioids in human subjects. However, there has been no previous attempt to corre late the magnitude of EEG changes after opioid drug treatment to scores of mood and feeling state. In the present study, self-reports of mood and feeling state were correlated with the quantitative changes in the EEG produced by morphine in polydrug abusers with histories of opioid use and dependence.
MATERIALS AND METHODS

Subjects
Subjects were paid volunteers who resided on a closed research ward for the duration of the study. Nineteen subjects emolled in the study, but data were only avail able for twelve. EEG data from seven of the subjects was not retained either because of equipment failure or because the subjects had subjective responses that were not characteristic of polysubstance abusers th at are emolled in studies at the Addiction Research Cen ter (i.e. , extremely weak response to 30 mg intramus cular (IM) morphine or strong response to placebo). The remaining 12 subjects were 26-39 years of age (mean = 35; SD = 4.5). A recent history of intravenous usage of opioids was a criterion for admission. The time from the last use of opioids prior to admission to the study was 3 (4) (mean [SD]) weeks. Subjects were confi.rmed to be opiate-free by urine testing prior to admission and while in the study. Screening instruments included the Na tional Institute of Mental Health (Bethesda, MD) Diag nostic Interview Schedule (Robins et al. 1981) , as mod ifled for computerized administration. Full details of the screening process are presented elsewhere (London et al. 1990 ). All but one subject met DSM-III (1980) criteria for opioid dependence, although none showed signs of physical dependence at the time of admission or dur ing participation in the study. Most other diagnoses for which Axis I criteria were met related to substance abuse disorders; however, one subject met criteria for psy chosexual dysfunction, one met criteria for simple pho bia, and two met criteria for agoraphobia. Axis II diag noses of borderline personality disorder (one subject) and antisocial personality disorder (three subjects) were also allowed.
All subjects gave informed consent to the proce dures in the protocol, which was approved by the In stitutional Review Boards of Johns Hopkins Medical In stitutions and Francis Scott Key Medical Center, where the NIDA Addiction Research Center is located.
Drug Treatments
Morphine sulfate (Mallinckrodt, Paris, KY) was dis solved in 0.9% NaCl at a concentration of either 15 or 30 mg/ml as the salt. The control vehicle was 0.9% NaCl. Doses of morphine were presented in ascending order to reduce the chance of untoward effects. A saline con trol session was randomly inserted in the sequence. Ad ministration was by 1M injection in a volume of 1 ml. The test compounds were administered double-blind. The doses were selected from previous data showing that 60% and 95% of detoxifi.ed, previously opioid dependent, human subjects could correctly discrimi nate 15 mg and 30 mg of morphine 1M as an opioid drug rather than a sedative or marijuana (Kay et a1. 1967 ).
Test Sessions
Subjects were administered the Morphine-Benzedrine Group (MBG); Pentobarbital Chlorpromazine Alcohol Group (PCAG); and lysergic acid diethylamide (LSD) subscales of the Addiction Research Center Inventory (ARCI) Oasinski et al. 1967; Haertzen 1974} and the Sin gle Dose Questionnaire (SDQ) (Fraser et al. 1961; Jasin ski et al. 1971) . The MBG subscale consists of 16 ques tions, which relate primarily to positive effects on mood. The PCAG subscale primarily measures sedation and lethargy. The LSD subscale is sensitive to weird feel ings, disorientation, and increased awareness of bodily sensations. The SDQ consists of questions relating to the identifi.cation and liking of drugs. Subjects also rated the strength of the treatment effect and their liking of it on six 100-mm visual line analog scales (VAS) similar to those used by others (Preston et a1. 1988) . The six questions from the VAS are listed in Table 1 . These questionnaires were administered 45 minutes after in jection of the test compound.
During the 45-minute measurement of spontane ous EEG, the subject was blindfolded and listened to a tape of white noise on which was recorded a beep tone at l-minute intervals. At the sounding of this tone, the subject was to respond to the question "How high do you feel?" on a scale of 0 ("no effect") to 4 ("ex tremely"). Pupillary diameter was measured from pho tographs taken of the subject's eyeball at 30 minutes before injection of the test compound (before the blind fold was applied) and at 45 minutes after injection of the test compound (after the blindfold had been re moved). Pulse and blood pressure were measured 60 and 30 minutes before and 10, 20, and 45 minutes after injection of the test compound.
EEG Recording
Electrodes made of Ag/ AgCl (Beckman Instruments, Irvine, CAl were attached to the scalp by collodion or adhesive collars according to the international ten twenty system (Jasper 1958) . All montages included leads F3, F4, F7, FB, T3, T4, C3, C4, 01, 02, P3, and P 4 .
Some also included leads Cz, Fpz, Fz, Pz, Oz, Ts, T6, Fp1, and Fp2. All leads were referenced to the left ear (A1). Eight subjects had 12-lead montages; the last four sub jects had 21-lead montages. Data from only the twelve leads common to all subjects were used for analysis.
Data from eight of the subjects were recorded in analog mode using an FM tape recorder at a recording speed of 15/16 inches/second, and subsequently were digitized into a computer off-line. Data from the last four subjects were digitized directly, using a different computerized system. In all cases, the data were digi tized at 200 samples/second/channel. The data were ac quired for a 3-minute period before injection (baseline) and for a 45-minute period starting immediately after administration of the test compound.
Digitized EEG data were reformatted using programs written by one of the authors (RLP) for use in the EEGSYS software system (Friends Medical Science Re search Center, Baltimore, MO). The data were screened by a blinded, trained technician ior artifacts due to eye motion or facial motion, using the DIS program of the EEGSYS software. Such artifacts generally occurred in conjunction with the ''beep'' prompts. During some recording sessions, one or more leads became detached. When this occurred, data from that lead were rejected, but data from other leads were used.
An autoregressive fllter (Coppola 1979 ) with a time constant of 200 msec. was used to remove low frequency harmonics from the remaining data. The effect of the fllter was to reduce power at frequencies <0.5 Hz by at least a factor of 2, while not appreciably affecting power at frequencies >1 Hz. The data were analyzed using a 2. 56-second (512-data point) epoch by fast Fou rier transform. The resulting spectra were averaged over 3-minute intervals. The power spectra were summed to form banded data based on frequency (f) as follows:
delta (1 � f < 6 Hz), theta (6 � f < 8.5 Hz), alpha (8.5 � f < 10.5 Hz), alpha2 (10.5 � f < 12.5 Hz), beta1 (12 � f < 18.5 Hz) and beta2 (21 � f < 30 Hz). The selection of bands was based on previous results showing that these bands reduce the amount of data without sacrificing useful drug-related information (Coppola and Hermann 1987) . Finally, the data were transformed to percent change from baseline. The power-weighted mean fre quency within each frequency band was also calculated.
Analysis
Self-reports of mood and feeling state (on MBG, PCAG, LSD subscales of ARCI and on VAS) were tested for NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.3 significant effects of drug by a one-way repeated mea sures analysis of variance (ANOVA). When a significant effect of drug was found, post hoc tests using matched pair t-tests with a Bonferroni correction were performed to assess significance of differences between placebo and each dose of morphine and between the two doses of morphine (three t-tests per variable).
Data on spectralized abundance were analyzed by a three-way ANOV A (LEAD x TIME x TREATMENT) for each spectral band using the SAS (SAS Institute, Cary, NC) procedure GLM (General Linear Models). A second set of analyses were performed in a mixed ANOV A (LEAD x TIME x TREATMENT) and regres sion (MBG, LSD, or PCAG score) analysis. The mixed ANOV A calculated an overall signi£lcance of the regres sion analysis used to determine correlations between the two types of continuous variables. The analyses treated TIME as a repeated measure and all other effects as between-subjects factors. Data used in the LEAD factor were from the 12 leads common to all subjects. The probability (p) values were adjusted using the Greenhouse-Geisser correction where appropriate.
Post hoc Bonferroni-corrected t-tests were per formed using the MEANS option of the GLM proce dure or the MEANS procedure from the SAS program system. Further post hoc analysis included correlation analysis between changes in power in each of the six spectral bands, analyzed during each of the three test sessions, with scores on the MBG, LSD, and PCAG sub scales of the ARC! and the VAS scores obtained 45 minutes after injection of the test compound. Correla tion analyses were only performed when the mixed regression ANOV A analysis showed a signifIcant corre lation effect, corrected for effects of TIME, LEAD, and TREATMENT. The dependent variable in all cases was the average spectral power; the independent variable was the score from the self-report scale.
RESULTS
There were no significant effects of morphine or placebo on heart rate or blood pressure; however, morphine caused a significant, dose-dependent decrease in pupil lary diameter (F = [11.3], df = [2, 8], P < .005 for a main effect of TREATMENT). Post hoc tests showed that pu pil size in each of the three drug conditions were signifI cantly different from one another (placebo, 15 and 30 mg morphine). The results on the SDQ indicated that 12, 3, and 1 subjects identified the test compound as ''blank'' when given saline, 15 mg and 30 mg morphine, respectively. None of the subjects ever identi£led the test substance as any drug other than "dope." Table 1 shows the effects of morphine on responses to the VAS. Scores for the £lve questions relating to posi tive effects (questions 1, 2, 4, 5, and 6) showed a gener- ally dose-dependent increase by morphine. The re sponses to these questions were highly correlated with one another. Correlation coefficients ranged from 0.74 to 0.995 between any two questions in each test condi tion. The lowest correlations involved question 6 ("How much do you want to take the drug again?"). There was no signibcant change from zero in response to the ques tion "Does the drug have bad effects?" Coefficients of f\J 0.4 were obtained for the correlation of VAS score with alphal power after treatment with either dose of morphine; there were smaller correlation coefficients for other bands and test conditions. The correlation coefficients were not signifIcant for any lead nor for the average of all leads but did achieve statistical signifI cance for calculations including each lead separately in one analysis. Four subjects showed no response to 15
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--0-30mgMS Figure 2 . Effect of morphine on the verbal response to the ques tion "How high do you feel?" A score of 0 was equivalent to the re sponse "not at aU"; increasing scores were equivalent to re sponses of "slight," "moderate," "high," and "extremely high." Note the dose-dependent response to morphine. Subjects were in structed to score their responses to this question every time they heard a "beep" prompt, which was recorded over white noise and presented via earphones.
mg morphine; one also showed no response to 30 mg morphine. Figures 2 and 3 show subjective self-reports of the effects of morphine. The response (prompted by the "beep") to the question "How high do you feel?" was immediate (Fig. 2) . The onset of the response was faster and the magnitude was larger when the higher dose of morphine was given. The ARCI revealed an increase in the MBG score in response to morphine (Fig. 3) Results of Multivariate ANOVA testing whether the different drug treatment conditions (TREATMENT), leads (LEAD), or time after injection (TIME) have statistically signifIcant effects on the percent change in spectral power during the f1rst 45 minutes after injection of test compound. Separate ANOVA procedures were performed for each spectral power band. The p value shown for the effect of TIME and the interaction of TIME and TREATMENT is the Greenhouse-Geisser adjusted p value where appropriate.
were no signilicant post hoc comparisons. Morphine did not signilicantly affect responses on the LSD sub Table 2 shows the results of ANOV As testing the effects of morphine on percent change in spectral power. There were no signilicant effects of LEAD nor of any interaction term involving LEAD. A confrrma tory factor analysis showed that, for each treatment con dition and band, a single factor explained 75% to 95% of the variance across TIME and LEAD. This factor was loaded equally into all leads.
Figures 4, 5, and 6 show the time course of the per cent change in spectral power over the duration of the experiment. Delta power increased in the placebo condi tion (Fig. 4a) . The increase was reversed by both doses of morphine, and was shown by a signifJ.cant main effect of TIME and a signilicant interaction of TIME with TREATMENT. Individual ANOVAs at each time per formed by repeated-measures-contrast ANOV A showed that, at most times after injection, there was a signifJ.cant effect of TREATMENT. Figure 4b shows the effects of morphine on percent change in theta power. There was a signilicant effect of TREATMENT as well as of TIME and a TREATMENT -with-TIME interaction. There was an increase in theta power during the &rst 12 and last 6 minutes of the experiment in response to 30 mg mor phine. Theta power decreased slightly in response to the saline and the injections of 15 mg morphine. Figure 5 shows the effects of morphine on alpha power, separated into two bands, low (alpha1) and high (alpha2). Both bands showed signilicant effects of TREATMENT and TIME, and a signilicantly TREAT MENT-by-TIME interaction. These effects reflected an overall increase in alpha1 power in response to mor phine. The increase was greater after administration of morphine, particularly in response to the 30 mg dose. In this case, the increase after 24 minutes was 30% to 40% over baseline. During the &rst 15 minutes after in jection, there was an increase in alpha2 power that dissipated more rapidly after the injection of saline than after the injection of morphine. Figure 6 shows the results for beta power. Accord ing to repeated-measures ANOV A, both beta1 and beta2 
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12 15 18 21 24 27 30 33 power showed signifIcant effects of TREATMENT, TIME and a TIME-by-TREATMENT interaction. There was an increase in betal during the fust 15 minutes af ter injection of either placebo or morphine. The effect dissipated during the next 15 minutes; 24 minutes af ter the injection of 30 mg morphine betal increased. Beta2 increased during the hrst 15 minutes after injec tion and dissipated during the rest of the experiment. The duration of the increase in beta2 appeared to be dose related, lasting the longest after injection of 30 mg morphine. Table 3 shows the results of a test (by mixed ANOV A regression) for signifIcant correlation between change in EEG spectral power from baseline and scores on the three subscales of the ARC!. The procedure tested correlation of the score on each subscale nested within TREATMENT and LEAD. Positive correlations Beta 1 (12:5 f < 18. were found between change in theta, alpha, and beta power and MBG score; negative correlations were found with PCAG and the alphal and beta2 bands. The scores on the LSD subscale showed no tendency for correlation with EEG measures. There was no correla tion of changes in power in the delta band with any of the scores on the three subscales. After the ANOV A, individual correlation analyses were performed. In these analyses, each factor (TREAT MENT, LEAD, and TIME) were separated so that (3 x 12 x 15 = ) 540 correlation analyses were performed.
Without the ANOVA to provide a protecting analysis, a correction for multiple comparisons (such as that of Bonferroni) would have been necessary and a value p < 10-4 would have been the criterion for signihcance. With the covering analysis, we used an uncorrected p value less than .05 as the criterion for signifIcance.
Using the alphal band and lead F7 as an example, there were 10/15 and 12/15 times when the percent The procedure tests for a signifIcant correlation between change in EEG power in each band nested within the factors TREATMENT and LEAD but averaged over all 15 times after injection.
change in EEG power from baseline was signifIcantly correlated (p < .05) with the score on the MBG and PCAG subscales, respectively, in response to 30 mg morphine. The correlations never achieved statistical signifIcance in response to 15 mg morphine or placebo. The correlation of change in EEG power vs. score on the LSD subscale never attained statistical signifIcance. Figure 7 shows a typical example of the scatter plots illustrating the correlation. Similar fIndings were ob tained from all of the other eleven leads from which data were analyzed.
DISCUSSION
As slow-wave sleep is associated with an increase in delta power and a decrease in alpha power (Walter 1959) , morphine-induced decreases in delta power and in creases in alpha power suggest that opioids produce arousal in subjects tolerant to the sedative effects of these drugs. This view is consistent with reports that morphine produces psychomotor activation in rodents (Babbini and Davis 1972; Shuster et al. 1975; Joyce and Iversen 1979) . Because alphal and betaz power are nega tively correlated with scores on the PCAG subscale and positively correlated with scores on the MBG subscale of the ARCI, reduced sedation (inferred from the PCAG score) accompanies positive affect (indicated by the MBG score) induced by morphine. These fIndings sup port and extend previous observations that morphine, like other opioids, induces insomnia in men who are not physically dependent upon opioids but have his tories of opioid abuse (Kay et al. 1969) .
Differences in the behavioral response to morphine, depending on the subject population, may explain some of the discrepancies observed with regard to EEG effects caused by or associated with morphine. It is well es tablished that morphine is a sedating drug in normal subjects (Matejcek et al. 1988) . Naive users also reported dizziness, nausea, and headache in response to mor phine (Beecher 1959) . Conversely, in experienced users,
-500/0�---.----.----.--� 5 7.5 10 1 2 .5 15 positive effects of the drug may keep subjects interested during an experimental procedure when they otherwise would lose interest and might fall asleep. Although EEG activity recorded from a particular lead on the scalp does necessarily reflect cortical activ ity immediately below that lead, the absence of a signifIcant effect of LEAD in this study is consistent with the fInding that morphine produces an overall reduc tion of glucose metabolism throughout the entire cor tex (London et al. 1990 ). These findings imply that posi tive effects of morphine on mood in polydrug abusers involve large cortical areas or subcortical regions rather than discrete loci in the cortex.
MBG Score
Positive correlations were found between the changes in alpha1, alpha2, beta1, and beta2 power in re sponse to 30 mg morphine and scores on the MBG sub scale of the ARCl. In contrast, negative correlations were observed between changes in alpha1 and beta2 and scores on the PCAG subscale. These correlations im ply that positive effects of morphine, as measured by the MBG score, are related to increases in alpha and beta activity and to a reduction in sedation, as measured on the PCAG subscale. Although these correlations are consistent with the signifIcant increases in alpha power produced by morphine, statistically significant increases in beta power were not observed. The lack of a consis tent increase in beta power in response to morphine con trasts with the effects of cocaine, which clearly increases beta activity (Berger 1931; Heming et al. 1985) .
Despite marked differences in the behavioral and physiological activities of drugs of abuse, an emerging literature suggests that there are commonalities in the ac tions of these drugs, extending beyond their assign ment to pharmacological classes. These commonalities include the ability to activate neuronal systems that pro duce positive affective states and attribute "incentive salience" (Robinson and Berridge 1993) . In physiologi cal terms, a variety of studies performed in animals have implicated central dopaminergic systems in the com mon behavioral effects of abused drugs (Hubner and Koob 1993) . Studies in human volunteers have indi cated that a common effect of drugs of abuse in experi enced drug users is a reduction of cerebral· glucose me ta bolism (London and Morgan 1993) . The presenting fmdings with morphine extend observations with other drugs of abuse to indicate that an increase in alpha power may be another common action of drugs of abuse. Aside from the present and previous observations that mor phine increases alpha power (Lukas et al. 1982; Lukas 1991) , enhancement of alpha power has also been ob served after administration of cocaine (Berger 1931 ) and doses of alcohol that had positive effects on mood (Lukas et al. 1986a (Lukas et al. , 1986b Cohen et al. 1993; Lukas 1993) .
Identification of a physiological process that under lies the behavioral aspects of drug abuse would be an Morphine, EEG, and Subjective Self-Reports 179 important step in elucidating the addictive process. It appears that an increase in alpha power is related to the positive rewarding properties of morphine. Further in vestigation of the anatomical substrates of the drug induced increase in alpha power and its role in the acute and chronic effects of drugs of abuse appears to be war ranted.
